Acumen Pharmaceuticals (ABOS) Earnings Analysis
Acumen Pharmaceuticals (ABOS) has no confirmed upcoming earnings date. Last quarter (2026-03-26) it beat with EPS -0.41 USD vs -0.5 USD est (+18%). It has beaten estimates in 1/1 recent quarters (100%). Trailing P/E -1.18.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does ABOS next report earnings?
No confirmed upcoming earnings date is currently scheduled for ABOS. This page updates as the calendar is published.
ABOS earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-03-26 | -0.41 USD | -0.5 USD | +18% | Beat |
Beat rate: 1/1 (100%) over reported quarters with consensus data.
ABOS valuation and analyst view
| Trailing P/E | -1.18 |
|---|---|
| Trailing EPS | -1.79179 USD |
| Price / book | 1.60 |
| Dividend yield | 0.00% |
| Market cap | 0.13B |
| Analyst consensus | Buy (7 buy / 0 hold / 0 sell) |
Related research pages
Frequently asked questions
When is Acumen Pharmaceuticals (ABOS)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for ABOS. This page updates as the calendar is published.
Did ABOS beat earnings last quarter?
In its 2026-03-26 report, ABOS posted EPS of -0.41 USD versus a -0.5 USD estimate — a beat of 18%.
What is ABOS's earnings track record?
Over the last 1 reported quarters with consensus data, ABOS beat estimates 1 times (100%).
What is ABOS's current P/E ratio and EPS?
ABOS trades at a trailing P/E of -1.18 on trailing EPS of -1.7917949061401182 USD.
What do analysts rate ABOS?
Analyst consensus is "Buy" across 7 ratings (0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell).